Patents by Inventor Lee D. Arnold

Lee D. Arnold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20240025890
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: William W. TURNER, Lee D. ARNOLD, Hans MAAG, Leping LI, Mark G. BURES, Simon Nicolas HAYDAR, Samson FRANCIS
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • Hepatitis b core protein modulators
    Patent number: 11814376
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 14, 2023
    Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology Corporation
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20230212152
    Abstract: The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 6, 2023
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20230192663
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: February 14, 2023
    Publication date: June 22, 2023
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230078839
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 23, 2022
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
  • INHIBITORS OF RAF KINASES
    Publication number: 20230081390
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
  • TREATMENT OF CANCER WITH CDK12/13 INHIBITORS
    Publication number: 20230074545
    Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.
    Type: Application
    Filed: December 23, 2020
    Publication date: March 9, 2023
    Inventors: Eric A. MURPHY, John TYHONAS, Noelito TIMPLE, Toufike KANOUNI, Lee D. ARNOLD, Elisabeth GARDINER, Eric MARTIN
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20230044112
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 9, 2023
    Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230012463
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 12, 2023
    Inventors: William W. Turner, Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20220402896
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: July 7, 2022
    Publication date: December 22, 2022
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11524940
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 13, 2022
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20220388990
    Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 8, 2022
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20220380347
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: May 3, 2021
    Publication date: December 1, 2022
    Inventors: Lee D. Arnold, Uri Lopatin, Walter Keung
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11472793
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: October 18, 2022
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20220324844
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 13, 2022
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV
    Publication number: 20220241208
    Abstract: The present disclosure provides, in part, pharmaceutical compositions that comprise a spray dried dispersion which contains the disclosed compound, and optionally, pharmaceutical excipients. The pharmaceutical compositions of the disclosure may be used in the treatment of Hepatitis B (HBV).
    Type: Application
    Filed: May 22, 2020
    Publication date: August 4, 2022
    Inventors: Lee D. ARNOLD, George Koan WONG, Kirk HENNE, James Francis HULVAT, Sanjay KONAGURTHU, Ian Scott MCINTOSH, Matthew David WESSEL, Thomas REYNOLDS, Richard J. COLONNO, Uri A. LOPATIN
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox